Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Trastuzumab, Pertuzumab, Fulvestrant, and Culmerciclib in HR+/HER2+ Early-Stage Breast Cancer
NCT07857226Phase 2Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2026
- Primary completion
- Jun 2028
01
Overview
Phase 2, open-label, single-arm trial of culmerciclib in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Total Pathological Complete Response at 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07857226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07857226.